SECISBP2 Deficiency Causes a Lethal Perinatal Cardiomyopathy
Authors:
- Carlos C. Smith-DiazCSCarlos C. Smith-Diaz
- Natasha HendenNHNatasha Henden
- Natalie StewartNSNatalie Stewart
- Samantha BryenSBSamantha Bryen
- Mark GrahamMGMark Graham
- Alexandra ButtersABAlexandra Butters
- Adam T. PiersAPAdam T. Piers
- Amy BakerABAmy Baker
- David A. ElliottDEDavid A. Elliott
- Ebony RichardsonEREbony Richardson
- Edward FormainiEFEdward Formaini
Preprint
Abstract
Selenoproteins are a specialised group of proteins that incorporate selenium, an essential micronutrient, in the form of selenocysteine. The SECIS binding protein 2 (SBP2), encoded by SECISBP2 , is a crucial component of the selenocysteine incorporation machinery. SECISBP2 deficiency compromises selenoprotein synthesis, and its knockout causes embryonic lethality in mice. Selenium is critical to cardiac function, and nutritional deficiency causes Keshan disease, a progressive cardiomyopathy. Biallelic variants in SECISBP2 cause pleiotropic phenotypes including abnormal thyroid hormone metabolism, neurodevelopmental disorders and aortic aneurysms. No reported phenotypes to date include cardiomyopathy. We report a consanguineous South Asian family with a history of perinatal deaths due to progressive cardiomyopathy and intractable arrhythmias with a rare homozygous loss-of-function splice site variant in SECISBP2 . The SECISBP2 c.1303-2A>G variant was homozygous in four affected offspring and heterozygous in the parents. One child without cardiac disease did not carry this variant. RNA sequencing confirmed that almost all transcripts would undergo nonsense-mediated decay. Further, we observed a pronounced decrease in GPX1 and SELENOH selenoprotein mRNA, as well as a large decrease in SELENOH, GPX1, GPX3 and GPX4 cardiac protein abundance in homozygotes, a molecular hallmark of SECISBP2 deficiency. Notably, we observed a >12-fold decrease in cardiac GPX4, a key selenoprotein that suppresses lipid peroxidation and ferroptosis, suggesting a possible ferroptosis-mediated mechanism for heart failure. Our analysis suggests that c.1303-2A>G is likely the most damaging homozygous variant discovered to date. For the first time, we show that SECISBP2 is essential for human life, with almost complete loss-of-function causing a lethal perinatal cardiomyopathy characterised by pronounced cardiac selenoprotein loss.Keywords
Funding Information
- Medical Research Future Fund (MRFF) Cardiovascular Health Mission ((#2024269))
- New South Wales Health Cardiovascular Capacity Grant
- Philanthropic funding from Alexandra’s Mission and Heart of the Green in memory of Josh Avvenevole
- National Health and Medical Research Council Investigator Grants ((#2034308))
- National Health and Medical Research Council Investigator Grants ((#2009982))
- National Health and Medical Research Council Investigator Grants ((#2008376))
- National Heart Foundation of Australia Future Leader Fellowships ((#106732))
- National Heart Foundation of Australia Future Leader Fellowships ((#107192))
- MRFF Genomics Health Futures Mission Grant ((#2008820))
This publication has 47 references indexed in Scilit:
- Severe neurodevelopmental phenotype, diagnostic, and treatment challenges in patients with SECISBP2 deficiencyGenetics in Medicine, 2024
- GPX4, ferroptosis, and diseasesBiomedicine & Pharmacotherapy, 2024
- Selenoprotein P deficiency is associated with higher risk of incident heart failureFree Radical Biology and Medicine, 2023
- Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormonesCell, 2023
- Sedaghatian spondylometaphyseal dysplasia in two siblingsEuropean Journal of Medical Genetics, 2022
- seqr : A web‐based analysis and collaboration tool for rare disease genomicsHuman Mutation, 2022
- Sedaghatian-type spondylometaphyseal dysplasia: Whole exome sequencing in neonatal dry blood spots enabled identification of a novel variant in GPX4European Journal of Medical Genetics, 2020
- Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced FerroptosisCell, 2018
- A mutation in theSEPN1selenocysteine redefinition element (SRE) reduces selenocysteine incorporation and leads toSEPN1-related myopathyHuman Mutation, 2009
- Selenoprotein expression is essential in endothelial cell development and cardiac muscle functionNeuromuscular Disorders, 2007